Exendin-4 and linagliptin attenuate neuroinflammation in a mouse model of Parkinson's disease.
Exendin-4和linagliptin在帕金森氏病小鼠模型中減輕神經炎症。
Neural Regen Res 2023-05-05
Incretin Mimetics Restore the ER-Mitochondrial Axis and Switch Cell Fate Towards Survival in LUHMES Dopaminergic-Like Neurons: Implications for Novel Therapeutic Strategies in Parkinson's Disease.
Incretin類擬物恢復LUHMES多巴胺樣神經元的ER-粒線體軸並將細胞命運轉向存活:對帕金森氏病的新治療策略的意義。
J Parkinsons Dis 2023-11-21
A Dual GLP-1/GIP Receptor Agonist Is More Effective than Liraglutide in the A53T Mouse Model of Parkinson's Disease.
一種雙重GLP-1/GIP受體激動劑在A53T小鼠帕金森氏症模型中比利拉谷肽更有效。
Parkinsons Dis 2023-10-05
Glucagon-like peptide-1 class drugs show clear protective effects in Parkinson's and Alzheimer's disease clinical trials: A revolution in the making?
GLP-1類藥物在帕金森病和阿茲海默症臨床試驗中展現明顯的保護效果:一場革命正在醞釀中?
Neuropharmacology 2024-05-18
Type 2 diabetes mellitus/obesity drugs: a neurodegenerative disorders savior or a bridge too far?
第二型糖尿病/肥胖藥物:神經退行性疾病的救星還是一步太遠?
Ageing Res Rev 2024-05-18
To the Brain and Beyond: Neurological Implications of Glucagon-Like Peptide-1 Receptor Agonists.
通往大腦及其後:胰高血糖素樣肽-1 受體激動劑的神經學意涵。
J Neurosurg Anesthesiol 2024-07-31
Glucagon-Like Peptide-1 Receptor Agonists and Risk of Parkinson's Disease in Patients with Type 2 Diabetes: A Population-Based Cohort Study.
GLP-1 受體激動劑與 2 型糖尿病患者帕金森病風險:一項基於人群的隊列研究。
Mov Disord 2024-08-27